Focus Surgery posts 1994 results
Focus Surgery's net loss widened last year as the company geared up its sales and marketing effortfor Sonablate 200, which uses high-intensity focused ultrasoundto treat benign prostatic hyperplasia (SCAN 9/28/94). The Fremont,CA, firm reported total
Focus Surgery's net loss widened last year as the company geared up its sales and marketing effortfor Sonablate 200, which uses high-intensity focused ultrasoundto treat benign prostatic hyperplasia (SCAN 9/28/94). The Fremont,CA, firm reported total revenues for 1994 (end-December) of $1.6million, compared to total revenues of $1.9 million the year before.Focus Surgery's net loss grew to $7.7 million, compared to $6.6million in 1993. Sonablate 200 was granted German regulatory approvallast year and Focus has made six commercial sales worldwide. Focusis working on a premarket approval (PMA) application to the Foodand Drug Administration to sell the system in the U.S.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
